NeuroSense Therapeutics Ltd (NRSN) 6-K, filed Mar 30, 2022

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2022

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

11 HaMenofim Street, Building BHerzliya 4672562 Israel+972-9-799-6183(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On March 30, 2022, NeuroSense Therapeutics Ltd. issued a press release regarding a video presentation with corporate updates. A copy of the press release is filed herewith as Exhibit 99.1.

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated March 30, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: March 30, 2022	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

Exhibit 99.1

NeuroSense Therapeutics CEO Provides Key Corporate Update Video

CAMBRIDGE, Mass., March 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a video presentation with a corporate update from its Founder and CEO Alon Ben-Noon, View video here: https://youtu.be/MMXhD9DhPZg

Highlights of the presentation include the following:

Amyotrophic Lateral Sclerosis (ALS) ClinicalProgram for Lead Drug Candidate PrimeC

·	2 clinical studies commencing Q2 2022

Pharmacokinetic study to be conducted under an FDA IND on track to be initiated in the coming weeks
Phase IIb double-blind placebo controlled multinational study

·	Evaluation of PrimeC in these studies aims to confirm<br>the synergism of the compounds in this combination drug therapy and maximize its potential therapeutic effect
·	Phase IIb study with PrimeC's unique formulation<br>is expected to demonstrate even better results than those already demonstrated in the previous Phase IIa study which achieved its endpoints
---	---
·	Investigation of ALS biomarkers will continue in<br>conjunction with Massachusetts General Hospital and may assist NeuroSense to increase the probability of success in a future pivotal clinical<br>study
---	---

Pipeline and IP Coverage

·	Data are expected in Q2 2022 from a biomarker study<br>of NeuroSense's drug candidate CogniC in the treatment of Alzheimer's disease, which may lead to a groundbreaking clinical study
·	In H2 2022 data are expected from preclinical studies<br>of StabiliC in the treatment of Parkinson's disease, expected to lead to initiation of a Phase I/II study
---	---
·	Expansion of IP estate with a key patent granted<br>in the US and Australia with other territories expected to follow soon
---	---

Tune into the video for more on NeuroSense's progress to date and an overview of upcoming catalysts and milestones: https://youtu.be/MMXhD9DhPZg

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains "forward-lookingstatements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, containedin this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified bythe use of words such as "anticipate," "believe," "contemplate," "could," "estimate,""expect," "intend," "seek," "may," "might," "plan," "potential,""predict," "project," "target," "aim," "should," "will" "would,"or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-lookingstatements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptionsthat are difficult to predict and include statements regarding patent applications; the company's PrimeC development program; the potentialfor PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinicaltrials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potentialof any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events thatmay not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense TherapeuticsLtd. undertakes no duty to update such information except as required under applicable law.

For further information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183

NeuroSense Therapeutics Ltd 6-K, filed Mar 30, 2022

About this 6-K